Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Joseph M. Miller appointed CFO effective September 2, 2026, bringing over two decades of biotech and pharmaceutical finance experience.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Joseph M. Miller appointed CFO effective September 2, 2026, bringing over two decades of biotech and pharmaceutical finance experience
- Annual base salary $530,000 plus 40% target discretionary bonus, increasing ongoing executive compensation costs
- Inducement option for 200,000 shares, vesting over four years, creating potential shareholder dilution
- Change-of-control protection includes one-year salary, 150% target bonus, COBRA reimbursement, and full equity acceleration
- Non-change-of-control severance includes nine months’ salary continuation and COBRA reimbursement for up to nine months
Item 7.01 · Regulation FD Disclosure
- CFO appointment disclosed under Regulation FD, making the leadership change broadly available to investors
- Mr. Miller’s appointment may affect financial strategy, reporting, capital allocation, and investor communications
- Exhibit 99.1 contains the company’s press release and additional appointment details
Item EX-99.1 · Exhibit EX-99.1
- Joseph Miller appointed CFO, adding commercialization and public-biotech finance experience ahead of pivotal NOVA-2 results
- Miller previously supported Aurinia Pharmaceuticals through LUPKYNIS launch and commercial infrastructure expansion
- Appointment signals preparation for potential LB-102 commercialization in schizophrenia if approved
- Key investor risks remain clinical failure, regulatory rejection, funding needs and dependence on LB-102
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.